U.S. markets closed
  • S&P 500

    3,870.29
    -31.53 (-0.81%)
     
  • Dow 30

    31,391.52
    -143.99 (-0.46%)
     
  • Nasdaq

    13,358.79
    -230.04 (-1.69%)
     
  • Russell 2000

    2,231.51
    -43.81 (-1.93%)
     
  • Crude Oil

    59.61
    -1.03 (-1.70%)
     
  • Gold

    1,734.00
    +11.00 (+0.64%)
     
  • Silver

    26.83
    +0.15 (+0.57%)
     
  • EUR/USD

    1.2090
    +0.0031 (+0.25%)
     
  • 10-Yr Bond

    1.4150
    -0.0310 (-2.14%)
     
  • GBP/USD

    1.3961
    +0.0040 (+0.29%)
     
  • USD/JPY

    106.7220
    -0.0080 (-0.01%)
     
  • BTC-USD

    47,581.25
    -621.60 (-1.29%)
     
  • CMC Crypto 200

    950.55
    -36.10 (-3.66%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Decision Diagnostics Corp. (DECN) Investigation

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / December 23, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Decision Diagnostics Corp. ("Decision" or "the Company") (OTC:DECN). Investors who purchased Decision securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/decn.

The investigation concerns whether Decision and certain of its officers and/or directors have violated federal securities laws.

Earlier this year, Decision announced that it had a finger prick test that could detect the coronavirus and have results in under one minute. On December 17, 2020, the U.S. Securities and Exchange Commission ("SEC") filed a lawsuit alleging that the Company's claims were untrue. Following this news, Decision stock dropped over 40% on December 18, 2020.

If you are aware of any facts relating to this investigation, or purchased Decision shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/decn. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/622168/Bronstein-Gewirtz-Grossman-LLC-Notifies-Shareholders-of-Decision-Diagnostics-Corp-DECN-Investigation